Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis

Authors Prashant Kedia, Russell D Cohen

Published 15 November 2007 Volume 2007:3(5) Pages 919—927

Prashant Kedia1, Russell D Cohen2

1Pritzker Medical School, The University of Chicago, Chicago, IL, USA; 2Clinical Inflammatory Bowel Disease, Department of Medicine, Section of Gastroenterology, The University of Chicago Medical Center, Chicago, IL, USA

Abstract: First-line therapies in the treatment of patients with mild-to-moderate ulcerative colitis are sulfasalazine or one of the mesalamine derivatives. Mesalamine is popular given its safety profile and reasonable efficacy in many patients. However, compliance is poor with regimens demanding large number of pills dosed multiple times a day and non-compliance has been correlated with disease relapse. Mesalamine requires direct contact with the inflamed colonic mucosa. To avoid proximal absorption, a variety of delivery systems has been utilized to time the release of active mesalamine to the areas affected by colitis. The most common mesalamine release mechanisms include azo-bond prodrug carriers, pH-dependent dissolution, and moisture-sensitive product dispersion. Novel technology has resulted in the development and FDA-approval of a multi-matrix release (MMX) mesalamine. Pharmacodynamic studies suggest a reliable drug delivery system with homogenous release throughout the entire colon. By incorporating the largest amount of mesalamine (1.2 g) per pill, this new product dramatically decreases the number of pills needed to attain a therapeutic daily dosage, and is the first agent approved at once-daily dosing. These factors are expected to increase patient compliance with prescribed mesalamine dosing, and in turn decrease relapse rates of active ulcerative colitis.

Keywords: mesalamine, sulfasalazine, balsalazide, olsalazine, ulcerative colitis, inflammatory bowel disease

Download Article [PDF] 

Readers of this article also read:

Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii

Anand N, Sehgal R, Kanwar RK, Dubey ML, Vasishta RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:6355-6369

Published Date: 8 October 2015

A regenerative label-free fiber optic sensor using surface plasmon resonance for clinical diagnosis of fibrinogen

Nguyen TT, Bea SO, Kim DM, Yoon WJ, Park J-W, An SSA, Ju H

International Journal of Nanomedicine 2015, 10:155-163

Published Date: 27 August 2015

To what extent is clinical and laboratory information used to perform medication reviews in the nursing home setting? the CLEAR study

Mestres Gonzalvo C, Hurkens KPGM, de Wit HAJM, van Oijen BPC, Janknegt R, Schols JMGA, Mulder WJ, Verhey FR, Winkens B, van der Kuy PHM

Therapeutics and Clinical Risk Management 2015, 11:767-777

Published Date: 8 May 2015

Editorial - Clinical Epidemiology

Henrik Toft Sørensen

Clinical Epidemiology 2009, 1:17-18

Published Date: 27 February 2009

Targeting CD22 as a strategy for treating systemic autoimmune diseases

Thomas Dörner, David M Goldenberg

Therapeutics and Clinical Risk Management 2007, 3:953-959

Published Date: 15 November 2007

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

“Getting physical”: the management of neuropsychiatric disorders using novel physical treatments

Gin S Malhi, Colleen Loo, Catherine M Cahill, Jim Lagopoulos, Philip Mitchell, Perminder Sachdev

Neuropsychiatric Disease and Treatment 2006, 2:165-179

Published Date: 15 June 2006